These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34043023)

  • 1. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy.
    Liu Y; Long W; Zhang Z; Zhang Z; Mai L; Huang S; Han H; Zhou F; Dong P; He L
    World J Urol; 2021 Nov; 39(11):4183-4190. PubMed ID: 34043023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.
    Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
    Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation.
    Uhlig A; Uhlig J; Trojan L; Kim HS
    J Vasc Interv Radiol; 2020 Apr; 31(4):564-571. PubMed ID: 32127324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcomes of Stereotactic Body Radiotherapy in Patients with Synchronous and Metachronous Oligometastatic Renal Cell Carcinoma.
    Guler OC; Oymak E; Hurmuz P; Yavas G; Tilki B; Yavas C; Ozyigit G; Onal C
    Urol Int; 2023; 107(2):171-178. PubMed ID: 36455527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study.
    Onal C; Guler OC; Hurmuz P; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
    Strahlenther Onkol; 2022 Oct; 198(10):940-948. PubMed ID: 35695908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.
    Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G
    Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
    Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
    Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
    Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
    Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
    Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
    J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
    Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
    Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
    Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
    Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
    Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
    Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
    Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
    Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.
    Franzese C; Franceschini D; Di Brina L; D'Agostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M
    J Urol; 2019 Jan; 201(1):70-76. PubMed ID: 30179619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
    Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
    Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.
    Miccio JA; Oladeru OT; Jun Ma S; Johung KL
    Urol Clin North Am; 2020 Aug; 47(3):399-411. PubMed ID: 32600541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).
    Altoos B; Amini A; Yacoub M; Bourlon MT; Kessler EE; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
    Radiat Oncol; 2015 Oct; 10():218. PubMed ID: 26510665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.